Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 79.43% is in line with its 5-year average of 85.07%, around the middle of its 5-year range (73.22%–92.44%).
1.38% below its 12-month average of 80.54%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 76.96%.
GROSS MARGIN
79.43%
GROSS MARGIN AVG TTM
80.54%
GROSS MARGIN AVG 3Y
82.82%
GROSS MARGIN AVG 5Y
85.07%
GROSS MARGIN AVG 10Y
88.82%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1.38%
CURRENT VS 3Y AVG
-4.09%
CURRENT VS 5Y AVG
-6.63%
CURRENT VS 10Y AVG
-10.57%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+91.95%
vs the sector median at left
Market Cap
$117.76M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
50.00%
5Y Avg
33.33%
Market Cap
$115.67M
Gross Margin
89.22%
TTM Avg
94.61%
3Y Avg
97.31%
5Y Avg
-2138.81%
Market Cap
$118.59M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$118.83M
Gross Margin
90.14%
TTM Avg
48.16%
3Y Avg
49.08%
5Y Avg
32.72%
Market Cap
$114.46M
Gross Margin
-60.26%
TTM Avg
-75.23%
3Y Avg
-314.56%
5Y Avg
-212.54%
Market Cap
$113.89M
Gross Margin
-7075.00%
TTM Avg
-9131.25%
3Y Avg
-4667.52%
5Y Avg
-3111.68%
Market Cap
$113.77M
Gross Margin
99.91%
TTM Avg
-67.10%
3Y Avg
-31.47%
5Y Avg
-20.98%
Market Cap
$119.84M
Gross Margin
-62.76%
TTM Avg
-61.84%
3Y Avg
-230.63%
5Y Avg
-163.28%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MaxCyte, Inc. (MXCT) | $116.76M | 79.43% | 80.54% | 82.82% | 85.07% |
| Spruce Biosciences, Inc. (SPRB)vs › | $117.76M | 0.00% | 50.00% | 50.00% | 33.33% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | 89.22% | 94.61% | 97.31% | -2138.81% |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $118.59M | 0.00% | 0.00% | 0.00% | 0.00% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.83M | 90.14% | 48.16% | 49.08% | 32.72% |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.46M | -60.26% | -75.23% | -314.56% | -212.54% |
| Genelux Corporation (GNLX)vs › | $113.89M | -7075.00% | -9131.25% | -4667.52% | -3111.68% |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | 99.91% | -67.10% | -31.47% | -20.98% |
| Cibus, Inc. (CBUS)vs › | $119.84M | -62.76% | -61.84% | -230.63% | -163.28% |
| Seer, Inc. (SEER)vs › | $120.41M | 46.31% | 49.33% | 27.70% | -6.64% |
Gross Margin
79.4%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 76.96% |
| 2026-03-31 | 73.22% |
| 2025-12-31 | 77.95% |
| 2025-09-30 | 92.44% |
| 2025-06-30 | 82.14% |
| 2025-03-31 | 85.59% |
| 2024-12-31 | 73.76% |
| 2024-09-30 | 76.38% |
| 2024-06-30 | 85.73% |
| 2024-03-31 | 87.63% |
| 2023-12-31 | 89.96% |
| 2023-09-30 | 90.09% |
| 2023-06-30 | 84.78% |
| 2023-03-31 | 88.34% |
| 2022-12-31 | 87.55% |
| 2022-09-30 | 87.14% |
| 2022-06-30 | 88.34% |
| 2022-03-31 | 90.83% |
| 2021-12-31 | 87.92% |
| 2021-09-30 | 90.69% |
| 2021-06-30 | 88.96% |
| 2021-03-31 | 89.33% |
| 2020-12-31 | 89.35% |
| 2020-09-30 | 89.13% |
| 2020-06-30 | 90.95% |
| 2020-03-31 | 88.52% |
| 2019-12-31 | 89.01% |
| 2019-09-30 | 89.01% |
| 2019-06-30 | 87.54% |
| 2019-03-31 | 87.54% |
| 2018-12-31 | 88.84% |
| 2018-09-30 | 88.84% |
| 2018-06-30 | 89.13% |
| 2018-03-31 | 89.13% |
| 2017-12-31 | 89.66% |
| 2017-09-30 | 89.66% |
| 2017-06-30 | 89.55% |
| 2017-03-31 | 89.55% |
| 2016-12-31 | 89.18% |
| 2016-09-30 | 89.18% |
| 2016-06-30 | 89.54% |
| 2016-03-31 | 89.54% |
| 2015-12-31 | 88.82% |
| 2015-09-30 | 88.82% |
| 2015-06-30 | 88.99% |
| 2015-03-31 | 88.99% |
| 2014-12-31 | 86.66% |
| 2014-09-30 | 86.66% |
| 2014-06-30 | 86.61% |
| 2014-03-31 | 86.61% |
